drugset / Trial / NCT03971929

Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension

NCT03971929

Phase 1 Completed 36 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

The study is being conducted to evaluate the safety and efficacy and Pharmacokinetics/Pharmacodynamics of SHR0532 in subjects with mild hypertension for 4 weeks.

Timeline

Start
2019-07-31
Primary completion
2020-09-03
Completion
2020-09-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydrochlorothiazide Unknown 25 mg Oral
Subject SHR0532 Unknown Oral

Indications